3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
7
Prostatic Neoplasms
6
Carcinoma, Renal Cell
6
Sarcoma
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lymphoma, Non-Hodgkin
3
Kidney Neoplasms
3
Glioma
3
Colonic Neoplasms
3
Wilms Tumor
2
Urinary Bladder Neoplasms
2
Thyroid Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Rectal Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms
2
Multiple Myeloma
2
Melanoma
2
Medulloblastoma
2
Lung Neoplasms
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Hematologic Neoplasms
2
Ependymoma
2
Endometrial Neoplasms
2
Interventions
belzutifan
2
Everolimus
2
Blood Specimen Collection
2
tanespimycin
1
spartalizumab
1
palbociclib
1
lenvatinib
1
cabozantinib
1
Sunitinib
1
PT2385
1
Oxygen-15
1
Nivolumab
1
Fluorodeoxyglucose F18
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
palbociclib
×
Genitourinary
×
Clear all
NCT07405164
2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3
Recruiting
450 enrolled